Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, May 2000, p. 444-450, Vol. 7, No. 3
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Susceptibility of Vibrio cholerae O139
to Antibody-Dependent, Complement-Mediated Bacteriolysis
Stephen R.
Attridge,1,*
Firdausi
Qadri,2
M. John
Albert,2 and
Paul A.
Manning3
Microbial Pathogenesis Unit, Department of
Microbiology and Immunology, The University of Adelaide, Adelaide,
South Australia 5005, Australia1;
International Centre for Diarrhoeal Disease Research,
Bangladesh, Dhaka 1000, Bangladesh2; and
Astra Research Centre Boston, Cambridge, Massachusetts
02139-42393
Received 15 October 1999/Returned for modification 21 December
1999/Accepted 17 February 2000
 |
ABSTRACT |
Volunteer studies with Vibrio cholerae O1 have shown
that the best correlate of a vaccine's protective efficacy is its
propensity to elicit serum bactericidal responses in its recipients.
Attempts to detect such responses following infection with V. cholerae O139, however, have met with varying success. Using a
tube-based assay which involves viable counting, we now report that
strains of serogroup O139 can appear to be sensitive or resistant to a fixed concentration of complement in the presence of antibody, depending on assay conditions. Susceptibility to lysis is critically dependent on the availability of complement, but with O139 indicator strains this is not simply determined by the concentration of serum
added to the reaction mix. The nature of the assay diluent and the
concentration of indicator bacteria can also dramatically affect
bactericidal end points, whereas such variables have minimal significance with O1 indicator bacteria. Although some laboratories use
unencapsulated mutant strains to seek evidence of seroconversion following exposure to V. cholerae O139, this is not
necessary, and our findings question the significance of capsule
expression as a determinant of complement sensitivity when antibody is
present. The medium used for growth of the indicator strain and the
particular strain used appeared to be unimportant. Each of seven O139
isolates tested was found to be lysed by antibody and complement in our standard assay system, which allowed the detection of significant serum
bactericidal responses in 9 of 11 cases of O139 disease.
 |
INTRODUCTION |
Until recently, only Vibrio
cholerae strains of the O1 serogroup had been associated with
epidemics of cholera. However, in 1992, outbreaks in India and
Bangladesh were attributed to isolates of a newly recognized serogroup,
O139 (5, 16). Subsequent investigation suggested that this
serogroup arose from an O1 strain of the El Tor biotype by acquisition
of foreign DNA involved in the synthesis of serogroup-determining O
antigen (4, 20). The resulting lipopolysaccharide (LPS)
structure differs not only in the composition of the O-antigen repeat
unit but also in that only 1 such subunit is linked to the core,
compared with almost 20 in the case of the O1 serogroup
(14). In addition, V. cholerae O139 strains
produce a capsule which is thought to comprise additional polymerized
O-repeat units which are not attached to the core structure (10,
23). This capsule has been associated with serum resistance
(10, 23).
In some locations, V. cholerae O139 displaced V. cholerae O1 as the primary cause of cholera (5, 16). In
contrast to the age-related incidence of O1 disease normally seen in
regions where cholera is endemic, the majority of O139-related cholera victims were adults (5, 16). This indicated that the natural immunity to V. cholerae O1 acquired by older inhabitants of
areas of endemicity afforded no protection against V. cholerae O139, suggesting that vaccines targeted against the O1
serogroup would be similarly ineffective against O139 strains. The rate
at which the new serogroup spread to neighboring countries prompted
fears of an eighth cholera pandemic, superimposed upon the continuing seventh pandemic caused by O1 El Tor strains (16).
Accordingly, researchers were quick to begin the quest for an effective
O139 cholera vaccine.
Volunteer studies revealed that the clinical profile of O139 disease
was similar to that previously observed with O1 strains. An initial
immunizing infection with pathogenic O139 vibrios (15), or
administration of the live O139 vaccine candidate CVD112
(21), conferred a high degree of immunity to subsequent
homologous rechallenge. In neither case, however, was this state of
immunity accompanied by a detectable increase in the titer of serum
bactericidal antibodies. This contrasts with earlier volunteer studies
with V. cholerae O1, in which a vaccine's capacity to
elicit bactericidal responses provided the best indicator of its
protective efficacy (12). The failure of O139 strains to
induce such responses was suggested to be the result of the capsule
shielding underlying LPS and thereby reducing its immunogenicity
(15, 21).
In other studies, however, oral immunization with live attenuated
(7) or chemically inactivated (8) V. cholerae O139 has resulted in detectable serum bactericidal
responses. Since the vaccine strains used in these studies also produce
capsules, the basis for this inconsistency is unclear. The present
report addresses the possibility that studies in which bactericidal
responses have not been reported reflect a failure to detect, rather
than a failure to elicit, antibodies with complement-dependent lytic activity. Whereas V. cholerae O1 is readily and reliably
lysed by complement in the presence of specific antibody, this is not the case with O139 strains. One report (18) suggested that
only certain O139 isolates were sensitive to antibody-dependent
bacteriolysis, while other groups have used unencapsulated mutants as
indicator strains to assist measurement of bactericidal responses
following O139 infection (7, 13).
The apparently conflicting reports concerning the induction of serum
bactericidal responses following exposure to V. cholerae O139 emanate from laboratories which employ microtiter plate-based bactericidal assay systems. The ability to assess killing
spectrophotometrically makes it feasible for these groups to screen
large numbers of serum samples, but it seems possible that this assay
system might itself be a limiting factor in the detection of
complement-fixing antibodies. For many years we have used a
bactericidal assay which is performed in tubes and involves viable
counting to assess residual bacterial survival. Using this method, we
have been able to consistently demonstrate lysis of wild-type O139
strains. Given the potential value of serum bactericidal responses as
an aid to O139 vaccine development, it seemed worthwhile to consider
the ways in which the assay systems differ, in the hope of identifying
those variables of greatest significance with respect to the
susceptibility of O139 to antibody and complement. We now report that,
depending on the conditions of the assay system, O139 vibrios can
appear to be sensitive or resistant to antibody and complement. It has not been possible to correlate this phenotype with differential expression of surface capsule. Using our standard bactericidal assay,
each of seven O139 isolates was sensitive to lysis, and significant
serum responses were detected in 9 of 11 cases of O139 disease.
 |
MATERIALS AND METHODS |
Bacterial strains.
V. cholerae AI1837, AI1838,
AI1841, AI1852, AI1854, AI1855, AI4260, and AI4450 are strains of
serogroup O139 isolated in Bangladesh. V. cholerae H1 and
174 are of serogroup O1 and El Tor biotype. Bacteria were grown with
vigorous shaking for 3 to 4 h at 37°C in either Oxoid Nutrient
Broth (OX) (10 g of Oxoid Bacteriological Peptone per liter, 10 g
of Oxoid Lab-Lemco Powder per liter, 5 g of NaCl per liter),
Luria-Bertani medium (LB) (10 g of Difco Bacto Tryptone per liter,
5 g of Difco Bacto Yeast Extract per liter, 10 g of NaCl per
liter, pH 7.0), or Difco brain heart infusion (BHI).
MAbs and patient sera.
Five monoclonal antibodies (MAbs)
directed against LPS of serogroup O139 were used. Four (ICL 9 [immunoglobulin M {IgM} isotype], ICL11 [IgG3], ICL12
[IgG2b], and ICL13 [IgM]) have been described elsewhere and shown
by a variety of assays to be sensitive diagnostic reagents for V. cholerae O139 (17); ICL 16 is of the IgM isotype. MAb
20B is specific for the A determinant of O1 serogroup LPS and from
previous studies (S. R. Attridge, unpublished data) is known to be
lytic for V. cholerae O1 in the presence of complement. An
IgG fraction of a polyclonal rabbit antiserum raised against viable
569B bacteria (V. cholerae O1) was also used in bactericidal assays; this was absorbed with a 569B-165 hybrid strain to make it
specific for O1 LPS as described previously (1). Serum and plasma samples were obtained from patients with bacteriologically confirmed O139 or O1 cholera. An initial acute-phase sample was taken
on day 2, and a later sample (following convalescence) was taken on day
11 or 22; for convenience these are referred to as pre- and
postinfection samples.
Bactericidal assays.
MAbs and patient sera were tested for
their potential to effect complement-dependent lysis of V. cholerae. Antibodies were serially diluted (three- or fourfold
dilutions in 150 to 200 µl) in assay diluent (see below) in 7.5- by
1.0-cm glass tubes. The indicator strain was usually grown to ca.
5 × 108 cells per ml in OX or LB, although killing
end points were similar regardless of the growth phase at which the
bacteria were harvested. After centrifugation, bacteria were
resuspended in homologous culture medium (CM) and then diluted to ca.
4 × 103 cells per ml in CM containing guinea pig
serum (usually at 20% vol/vol) as a source of complement. An equal
volume of this suspension was added to the serial dilutions of the test
antibodies (so that the final concentration of complement was generally
10%, vol/vol). The contents of the tubes were mixed, incubated at
37°C for 60 min, and transferred to an ice bath, and 50-µl aliquots
were plated to determine residual viability (relative to control tubes
lacking antibody). Bactericidal titers were obtained by interpolation of plots of percent survival versus log10 (reciprocal)
antibody dilution and represent reciprocals of the dilutions capable of killing 50% of the indicator vibrios.
Generally the assay diluent was the CM used to grow the indicator
strain. This represented an attempt to maintain the phenotype of the
vibrios during the period of the assay, since initial experiments suggested the CM might be an important determinant of bacterial susceptibility to lysis by antibody and complement. In some
experiments, however, bacteria were tested for sensitivity to MAb and
complement in either phosphate-buffered saline (PBS) (pH 7.2) or
heterologous CM.
Some assays were performed using mixed bacterial suspensions. We have
previously reported that introduction of a chromosomal
tcpA::Kan mutation does not alter the sensitivity
of O1 serogroup
V. cholerae to antibody-dependent,
complement-mediated lysis (
3).
A similar mutant was
available for the O139 strain AI1838 (
2),
and a preliminary
test confirmed that it also showed unaltered
susceptibility to lysis
when both mutant and parent strains were
grown and assayed in OX (data
not shown). The presence of the
Kan marker made it possible to
separately enumerate vibrios grown
in different CM in bactericidal
assays performed on mixed
suspensions.
Hemolysis assay.
Assay diluents (CM, PBS, or
Mg2+-saline [2 mM MgCl2 in 0.85% {wt/vol}
saline, pH 7.0]) were compared for possible inhibitory affects on
complement activity by using a hemolysis assay. Guinea pig serum (as a
complement source) was serially titrated, in duplicate in each diluent,
across the rows of a plastic microtiter tray. An equal volume (50 µl)
of rabbit hemolysin-sensitized sheep erythrocytes (at 1% [vol/vol]
in each diluent) was added, and the tray was shaken briefly. After
incubation at 37°C for 60 min, the tray was centrifuged and a
multichannel pipettor was used to transfer 50-µl supernatant samples
to a clean tray. Hemoglobin release was assessed by measuring the
optical density at 405 nm in an enzyme-linked immunosorbent assay plate
reader, and these readings used to plot percent lysis versus reciprocal
serum dilution.
EM.
Bacteria were sectioned and examined by electron
microscopy (EM) essentially as described elsewhere (9).
Vibrios were harvested from shaking cultures by centrifugation, washed
once in CM, and then fixed with glutaraldehyde (5% [vol/vol] in CM)
for 90 min at 37°C and then overnight at 4°C. After three washes in
PBS, the bacteria were incubated with polycationic ferritin (Sigma) (1 mg/ml), an electron-dense negative stain for capsular material, for 60 min at room temperature. Bacteria were washed twice in PBS, fixed with
1% osmium tetroxide, washed again in PBS, and then immobilized in 4%
agarose. The agarose was sliced into small fragments, and then samples
were dehydrated by exposure to increasing concentrations (30 to 100%)
of ethanol. After being washed in propylene oxide, the samples were
embedded in resin and sectioned. The thin sections were placed on
grids, stained with uranyl acetate, and examined under a Philips
transmission EM at 80 kV.
Immunoblotting.
AI1838 was grown in OX or LB for the normal
period of 3 to 4 h, or overnight to achieve greater cell
densities. After centrifugation, the bacteria were resuspended in PBS,
with volumes being adjusted on the basis of the optical densities of
the cultures at the time of harvest. An equal volume of 2× lysis
buffer was added, and the suspensions were boiled for 5 min before
overnight incubation at 56°C with proteinase K (0.1 mg/ml). Samples
were stored frozen until sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (ca. 5 × 109 bacteria were loaded per
lane) and transfer to nitrocellulose as described elsewhere
(22). MAbs to O139 polysaccharide were applied, and binding
was detected using horseradish peroxidase-conjugated anti-mouse IgG
followed by enhanced chemiluminescence (22).
 |
RESULTS |
Susceptibility of V. cholerae O139 to lysis by
antibody and complement.
Preliminary bactericidal assays confirmed
that MAbs directed against the O antigens of serogroup O1 or O139
mediate complement-dependent lysis of vibrios of the homologous
serogroup only (data not shown). These assays were performed using our
normal growth medium, OX, as CM and assay diluent. However, BHI is
commonly used to culture O139 indicator bacteria for use in plate-based
bactericidal assays (8, 19), while others have used LB
(7). Surprisingly, O139 vibrios grown (and assayed) in LB or
BHI were resistant to killing by antibody and complement (data not
shown, but see below). Each of five O139 strains showed a similar
medium-dependent susceptibility to complement in the presence of any of
five MAbs to O139 LPS, whereas O1 strains H1 and 174 were equally
sensitive whether grown in OX, LB, or BHI (data not shown).
Capsule expression by OX- and LB-grown V. cholerae
O139.
Strains of serogroup O139 have been reported to produce a
capsule following growth in LB, and this has been associated with complement resistance (23). Moreover, some groups use
unencapsulated mutants to facilitate detection of bactericidal
antibodies to O139 (7, 13). It was therefore of great
interest to ascertain whether the level of capsule synthesis might vary
in different CM and, if so, whether such variation parallels observed
differences in susceptibility to antibody and complement. AI1838, as
well as the O1 strain H1 as a control, was grown in OX, LB, and BHI. Washed bacteria were glutaraldehyde fixed, incubated with polycationic ferritin for detection of capsular material, and examined by EM.
Little or no ferritin binding was seen with H1 bacteria, regardless of
the CM used (Fig.
1A). In contrast, the
vast majority
of AI1838 bacteria were labeled after growth in BHI or LB
(Fig.
1B), although the level of ferritin binding was much less
dramatic
than that shown in other reports (
6). AI1838 grown
in OX showed
great variation in ferritin binding, as shown in Fig.
1C
to F.
While most bacteria showed no labeling, a significant minority
resembled the heavily encapsulated O139 vibrios described by others
(
6). The latter were consistently present in OX-AI1838
preparations
but were not seen in LB- or BHI-grown suspensions of the
same
strain.

View larger version (94K):
[in this window]
[in a new window]
|
FIG. 1.
Capsule production by V. cholerae. Ferritin
labeling in sections of OX-grown H1 (A) (magnification, ×52,000)
LB-grown AI1838 (B) (×39,000), and OX-grown AI1838 (C to F) (×39,000,
×21,000, ×21,000, and ×16,000, respectively) are shown.
|
|
Waldor et al. (
23) reported that O139 capsular material
could be visualized by immunoblotting whole-cell lysates
electrophoresed
on acrylamide gels. Using this approach, it was
possible to detect
polysaccharide running in the "medium migrating"
position of the
gel (
23); similar amounts of this material
were associated with
AI1838 bacteria following growth in LB or OX (not
shown).
Significance of assay diluent.
Other experiments examined the
impact of varying the diluent used in the bactericidal assay. Initially
AI1838 was cultured in OX or LB, and the organisms were harvested by
centrifugation and then washed and resuspended in PBS. The bacteria
were then tested for susceptibility to antibody and complement, either
immediately or after incubation in PBS at 37°C for 30 min, in
bactericidal assays using PBS as the diluent. All four suspensions were
equally sensitive to lysis by ICL11, with the titers (5.8 × 104 to 8.2 × 104) being typical of those
previously seen with AI1838 vibrios grown and assayed in OX. Similar
results were obtained in a subsequent experiment. OX- and LB-AI1838
cultures were subdivided, with one aliquot diluted in homologous CM for
estimation of the ICL11 bactericidal titer. The other aliquots were
spun, and the bacteria were resuspended and immediately diluted in PBS
for exposure to the same antibody. As shown in Table
1 (experiment A), LB-AI1838 was
effectively lysed when assayed in PBS, but no killing was observed in
LB diluent.
Further experiments showed that lysis of OX-grown AI1838 was also
diluent dependent. Strain AI1838 was cultured in OX or LB,
and then
each suspension was diluted (ca. 10
5-fold) in both media
for assessment of MAb (ICL11)-dependent,
complement-mediated lysis. As
shown in Table
1 (experiment B),
bacteria grown in either CM were
readily lysed if the assays were
performed in OX, but no killing was
detected in LB diluent. A
similar result was obtained when AI1838 was
grown in BHI then
assayed in BHI or OX; OX diluent was supportive of
bacteriolysis,
but BHI was not (Table
1, experiment
C).
These experiments indicated that susceptibility to lysis was determined
by the nature of the assay diluent rather than the
CM. Confirmation
that LB-grown AI1838 bacteria were not inherently
more resistant to
lysis came from assays performed on mixed suspensions
of LB- and
OX-grown vibrios. AI1838 and its
tcpA::Kan mutant,
which displays unaltered susceptibility to antibody and complement
(see
Materials and Methods), were each cultured in OX and LB.
Two mixed
suspensions were prepared in OX diluent, one with approximately
equal
concentrations of OX-grown AI1838 and LB-grown AI1838
tcpA::Kan
and the other with LB-grown AI1838 and
OX-grown AI1838
tcpA::Kan.
Aliquots of both
suspensions were incubated, in duplicate, with
complement alone or
additionally with either of two concentrations
of ICL12. After
incubation for 60 min at 37°C, all suspensions
were plated in
triplicate on nutrient agar with or without kanamycin.
The ratios of
wild-type to mutant bacteria recovered from tubes
containing antibody
(at concentrations resulting in ~65 or ~90%
killing) were not
consistently different from those in control
tubes. For the mixed
OX-AI1838-LB-AI1838
tcpA::Kan suspension,
these
ratios were 0.84, 0.87, and 0.78 respectively; for the reciprocal
suspension, they were 0.97, 1.36, and 1.58,
respectively.
The assay diluent influences efficiency of complement
activation.
One possible explanation for the variable,
diluent-dependent lysis of V. cholerae O139 is that the
assay diluent somehow influences the availability or function of one or
more of the complement subcomponents. This possibility was addressed in
a different assay system which also depends on complement activation.
Two batches of complement were separately titrated for lytic activity
against antibody-sensitized erythrocytes in a hemolysis assay. To
assess the significance of the assay diluent, parallel titrations were performed in OX, LB, PBS, or Mg2+-saline. Representative
data are shown in Fig. 2 and confirm that lytic activity is indeed dependent upon the diluent used. Of greatest relevance in the present context, LB medium was less supportive of
complement function than OX (a two- to threefold difference in lytic
end points [e.g., titers of 45 and 100, respectively, in Fig. 2]).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of assay diluent on sensitivity of
complement-mediated hemolysis. Percent hemolysis versus reciprocal
complement dilution using various assay diluents is shown. A, LB (50%
hemolytic titer, 45); B, OX (100); C, PBS (175); D,
Mg2+-saline (470).
|
|
This result offered an explanation for the apparent resistance of
LB-grown (and assayed) O139 to lysis by antibody and complement.
It
also suggested that it might be possible to achieve lysis of
such
bacteria by increasing the concentration of complement; conversely,
lysis of OX-O139 might be less efficient if the complement level
was
reduced. The effect of complement concentration on bactericidal
titers
was therefore examined, using indicator strains of either
serogroup and
LB or OX as the assay diluent. These results are
shown in Fig.
3.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of complement concentration on bactericidal
titer. The effect of varying complement concentrations on bactericidal
end points is shown. Antibodies of the IgG isotype (ICL11 versus
AI1838; polyclonal anti-V. cholerae versus H1) were titrated
against the appropriate indicator strain (AI1838 [ ] or H1 [ ])
using OX (solid lines) or LB (dotted lines) as the assay diluent.
|
|
The antibodies used were both of the IgG isotype and showed similar
bactericidal activities against the appropriate indicator
strain under
our standard assay conditions (OX diluent, 10% complement).
This
experiment (which was subsequently repeated with very similar
results)
shows that, by increasing the concentration of complement
to 30%, it
is indeed possible to lyse AI1838 even when LB is used
as the assay
diluent. Moreover, the titer observed is similar
to that seen at a
level of 10% complement in OX. In either case,
a threefold reduction
in complement concentration is sufficient
to completely prevent
antibody-dependent lysis (Fig.
3).
In contrast, bactericidal titers against the O1 indicator strain H1
were less dramatically affected by reductions in the level
of
complement. In OX diluent an initial 10-fold fall in complement
concentration resulted in only a fourfold reduction in lytic titer,
although further reductions had more marked effects on titers
(Fig.
3).
In LB diluent the effects of reducing complement levels
were more
pronounced, in line with the reduced efficiency of complement
fixation
in this medium (Fig.
3).
Other variables which may influence bactericidal end points.
In addition to the CM, the assay diluent, and the level of complement
added to the reaction mix, other parameters which vary in bactericidal
assays performed in different laboratories include the nature of the
indicator strain and the concentration of indicator bacteria. Of eight
O139 strains examined, seven were serum resistant, i.e., able to
survive incubation with complement in the absence of antibody. Each of
these strains was susceptible to lysis by MAb to O139 LPS in our
standard assay system.
Plate-based bactericidal assays use much higher concentrations of
indicator bacteria than that employed in our system. To
assess the
significance of this variable, parallel assays were
performed (in OX
diluent) using OX-grown vibrios of the O1 or
O139 serogroup present at
~2 × 10
3 or ~2 × 10
7 per ml. As
shown in Table
2, bactericidal titers
were reduced
at the higher concentration of indicator organisms,
whether the
antibodies were of the IgG or IgM isotype. Although this
effect
was fairly limited in assays with O1 bacteria, dramatic (16 to
53-fold) reductions were observed in bactericidal titers against
O139
strains.
Assessment of bactericidal responses following O139 cholera.
Paired serum samples from six bacteriologically confirmed cases of
cholera caused by strains of V. cholerae O139 were tested for evidence of bactericidal responses, using OX-grown AI1838 as the
indicator organism in our standard assay system (OX diluent, 10%
complement, ca. 2 × 103 bacteria per ml). Increases
in bactericidal titer ranging from 7- to over 80-fold were detected
(Table 3, group A). No significant increases in titer were observed when the sera were tested against OX-grown H1 (data not shown). Subsequently, paired plasma samples from
five O1 and five O139 cholera victims were also tested for bactericidal
activity against indicator strains of the homologous serogroup. All
five O1 patients, and three of five O139 patients, mounted significant
responses (Table 3, groups B and C).
The six pairs of serum samples which showed the greatest increase in
bactericidal titer against
V. cholerae O139 were reassayed,
using a higher concentration of OX-grown AI1838 indicator organisms
(ca. 2 × 10
7 per ml). The postinfection samples now
showed dramatically reduced
titers, resulting in much weaker apparent
responses (Table
3,
groups A and B). The geometric mean fold rise among
this limited
cohort was now only 3.6 (range, 1.2 to 8.6), compared with
53
(range, 17 to 200) under standard assay
conditions.
 |
DISCUSSION |
Whether grown in OX, LB, or BHI, V. cholerae O139 was
readily lysed in assays performed using OX diluent but not in those using LB or BHI (Table 1). EM (Fig. 1) and immunoblotting studies failed to reveal a difference in capsule expression which correlated with susceptibility to antibody and complement. Paradoxically, it was
only in samples prepared from OX-grown O139 that the thick capsules
described by others (6) were observed. The presence of a
significant minority of heavily encapsulated bacteria in suspensions
which showed uniform sensitivity to lysis suggested that capsular
material might not be responsible for the apparent resistance of LB-
and BHI-grown O139 strains to lysis by antibody and complement.
Other experiments suggested an alternative explanation for the link
between assay diluent and susceptibility to complement. Hemolysis
assays demonstrated an effect of the diluent on the efficiency of
complement activation (Fig. 2). In particular, lytic titers were higher
in OX than in LB, prompting an assessment of the consequences of
titrating complement levels in bactericidal assays performed using
these diluents. This showed that, even with LB as the assay diluent,
LB-grown AI1838 was indeed susceptible to antibody-dependent lysis if
the concentration of complement was increased threefold to a final
concentration of 30%. Under these conditions, the lytic titer of ICL12
was similar to that seen in our standard assay system, using OX-grown
AI1838 indicators (at ~2 × 103 per ml), OX diluent,
and 10% complement (Fig. 3). In either case a threefold decrease in
complement level completely abrogated bacteriolysis.
In the same experiments, lytic titers against the O1 indicator strain
were less dramatically affected by reductions in complement concentration (Fig. 3). Clearly, the level of complement added to the
assay system is a prime determinant of lytic sensitivity, but the
significance of these experiments lies in their implications for the
development of O139 bactericidal assays. Compared to the lysis of O1
vibrios, the demonstration of O139 lysis is much less tolerant of
suboptimal levels of complement. A similar difference between the
serogroups was evident when we assessed the effect of varying the
concentration of indicator organisms used in bactericidal assays.
Antibody titers against the O1 strain H1 fell ~3-fold in response to
a 104-fold increase in bacterial concentration, whereas
titers against AI1838 fell ~30-fold (Table 2). Evidently complement
becomes limiting at the higher concentration of the O139 strain,
confirming the notion that this serogroup is comparatively resistant to
killing by antibody and complement. The reason for this remains to be elucidated, but clearly one possibility is that the presence of capsular material competitively blocks binding of antibody to the
underlying core-linked O-antigen subunit. This might lead to
nonproductive fixation of complement on the bacterial surface, reducing
the availability of complement components to antibodies whose location
confers the potential for lysis.
When our standard assay system was used to seek evidence of
bactericidal responses following O139 or O1 cholera, seroconversion was
detected in 9 of 11 O139 patients and 5 of 5 O1 patients (Table 3).
Pre- and postinfection titers were generally lower against V. cholerae O139, but among responders the titer increases were of
similar magnitude with the two serogroups. This is consistent with the
findings of a recent, more comprehensive study (19). The
impact of using a higher concentration of indicator bacteria in the
O139 assay system was revealed by repeating the titration of the serum
pairs showing the greatest increases in lytic titer. The apparent
bactericidal responses were now dramatically lower (Table 3). The
requirement of plate-based assays for much higher concentrations of
indicator bacteria is therefore likely to seriously compromise
detection of bactericidal responses (Tables 2 and 3). This probably
explains why the use of selected mutant or variant strains of O139 is
sometimes necessary to demonstrate lysis by antibody and complement.
Using our system, however, all seven (serum-resistant) O139 isolates
examined were lysed in the presence of MAb to O139 LPS. Qadri et al.
(18) reported that AI1837 and AI1838, two of the strains
checked by us, did not allow the detection of bactericidal responses
following O139 infection, but theirs was a plate-based assay, with
indicator bacteria at 0.27 × 107 per ml and a final
complement concentration of only 5%. These workers used strain 4260B
as an indicator, following the demonstration that A and B variants can
be isolated from V. cholerae O139 strains. The A variants
resist killing by antibody and complement, whereas the B variants are
susceptible, even though both retain the capacity to produce a capsule
(11). This is consistent with the finding that in our assay
system, capsule production does not appear to be the major impediment
to lysis by antibody and complement.
The tube-based assay used in the present studies is suitable for
demonstrating lysis of V. cholerae O139 by antibody and
complement and for the detection of serum bactericidal responses after
infection by strains of this serogroup. Although comparatively labor
intensive, this assay can nevertheless be applied to 10 to 15 serum
pairs at a time and could therefore prove useful as an additional
measure of immunogenicity during testing of O139 candidate vaccines.
Clearly, however, plate-based assays are much more convenient than the viable counting approach used here. Studies are under way to define an
optimal combination of assay parameters which would allow us to combine
the sensitivity of the tube-based method with the screening power of
the plate-based assays.
 |
ACKNOWLEDGMENTS |
This study was supported by the Australian National Health and
Medical Research Council.
We thank Marilyn Henderson (Centre for Electron Microscopy and Micro
Analysis, The University of Adelaide) and Uwe Stroeher for assistance
with EM and Ann-Mari Svennerholm and Kevin Killeen for detailed
descriptions of their bactericidal assay systems.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Microbial
Pathogenesis Unit, Department of Microbiology and Immunology, The
University of Adelaide, Adelaide, South Australia 5005, Australia.
Phone: 61 8 8303 4151. Fax: 61 8 8303 4362. E-mail:
stephen.attridge{at}adelaide.edu.au.
 |
REFERENCES |
| 1.
|
Attridge, S. R.,
D. Daniels,
J. K. Morona, and R. Morona.
1990.
Surface co-expression of Vibrio cholerae and Salmonella typhi O-antigens on Ty21a clone EX210.
Microb. Pathog.
8:177-188[CrossRef][Medline].
|
| 2.
|
Attridge, S. R.,
P. A. Manning,
J. Holmgren, and G. Jonson.
1996.
Relative significance of mannose-sensitive hemagglutinin and toxin-coregulated pili in colonization of infant mice by Vibrio cholerae El Tor.
Infect. Immun.
64:3369-3373[Abstract].
|
| 3.
|
Attridge, S. R.,
E. Voss, and P. A. Manning.
1993.
The role of toxin-coregulated pili in the pathogenesis of Vibrio cholerae O1 El Tor.
Microb. Pathog.
15:421-431[CrossRef][Medline].
|
| 4.
|
Bik, E. M.,
A. E. Bunschoten,
R. D. Gouw, and F. R. Mooi.
1995.
Genesis of the novel epidemic Vibrio cholerae O139 strain: evidence for horizontal transfer of genes involved in polysaccharide synthesis.
EMBO J.
14:209-216[Medline].
|
| 5.
|
Cholera Working Group.
1993.
Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal.
Lancet
342:387-390[CrossRef][Medline].
|
| 6.
|
Comstock, L. E.,
D. Maneval, Jr.,
P. Panigrahi,
A. Joseph,
M. M. Levine,
J. B. Kaper,
J. G. Morris, Jr., and J. A. Johnson.
1995.
The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1.
Infect. Immun.
63:317-323[Abstract].
|
| 7.
|
Coster, T. S.,
K. P. Killeen,
M. K. Waldor,
D. T. Beattie,
D. R. Spriggs,
J. R. Kenner,
A. Trofa,
J. C. Sadoff,
J. J. Mekalanos, and D. N. Taylor.
1995.
Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype.
Lancet
345:949-952[CrossRef][Medline].
|
| 8.
|
Jertborn, M.,
A.-M. Svennerholm, and J. Holmgren.
1996.
Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine.
Vaccine
15:1459-1465.
|
| 9.
|
Johnson, J. A.,
P. Panigrahi, and J. G. Morris, Jr.
1992.
Non-O1 Vibrio cholerae NRT365 produces a polysaccharide capsule that determines colony morphology, serum resistance, and virulence in mice.
Infect. Immun.
60:864-869[Abstract/Free Full Text].
|
| 10.
|
Johnson, J. A.,
C. A. Salles,
P. Panigrahi,
M. J. Albert,
A. C. Wright,
R. J. Johnson, and J. G. Morris, Jr.
1994.
Vibrio cholerae O139 synonym Bengal is closely related to Vibrio cholerae El Tor but has important differences.
Infect. Immun.
62:2108-2110[Abstract/Free Full Text].
|
| 11.
|
Jonson, G.,
J. Osek,
A.-M. Svennerholm, and J. Holmgren.
1996.
Immune mechanisms and protective antigens of Vibrio cholerae serogroup O139 as a basis for vaccine development.
Infect. Immun.
64:3778-3785[Abstract].
|
| 12.
|
Levine, M. M., and C. O. Tacket.
1994.
Recombinant live cholera vaccines, p. 395-413.
In
I. K. Wachsmuth, P. A. Blake, and O. Olsvik (ed.), Vibrio cholerae and cholera. Molecular to global perspectives. ASM Press, Washington, D.C.
|
| 13.
|
Losonsky, G. A.,
Y. Lim,
P. Motamedi,
L. E. Comstock,
J. A. Johnson,
J. G. Morris, Jr.,
C. O. Tacket,
J. B. Kaper, and M. M. Levine.
1997.
Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity.
Clin. Diagn. Lab. Immunol.
4:264-269[Abstract].
|
| 14.
|
Manning, P. A.,
U. H. Stroeher, and R. Morona.
1994.
Molecular basis for O-antigen biosynthesis in Vibrio cholerae O1: Ogawa-Inaba switching, p. 77-94.
In
I. K. Wachsmuth, P. A. Blake, and O. Olsvik (ed.), Vibrio cholerae and cholera. Molecular to global perspectives. ASM Press, Washington, D.C.
|
| 15.
|
Morris, J. G., Jr.,
G. E. Losonsky,
J. A. Johnson,
C. O. Tacket,
J. P. Nataro,
P. Panigrahi, and M. M. Levine.
1995.
Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers.
J. Infect. Dis.
171:903-908[Medline].
|
| 16.
|
Nair, G. B.,
T. Ramamurthy,
S. K. Bhattacharya,
A. K. Mukhopadhyay,
S. Garg,
M. K. Bhattacharya,
T. Takeda,
T. Shimada,
Y. Takeda, and B. C. Deb.
1994.
Spread of Vibrio cholerae O139 Bengal in India.
J. Infect. Dis.
169:1029-1034[Medline].
|
| 17.
|
Qadri, F.,
T. Azim,
A. Chowdhury,
J. Hossain,
R. B. Sack, and M. J. Albert.
1994.
Production, characterization, and application of monoclonal antibodies to Vibrio cholerae O139 synonym Bengal.
Clin. Diagn. Lab. Immunol.
1:51-54[Abstract/Free Full Text].
|
| 18.
|
Qadri, F.,
G. Mohi,
J. Hossain,
T. Azim,
A. M. Khan,
M. A. Salam,
R. B. Sack,
M. J. Albert, and A.-M. Svennerholm.
1995.
Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1.
Clin. Diagn. Lab. Immunol.
2:685-688[Abstract].
|
| 19.
|
Qadri, F.,
C. Wenneras,
M. J. Albert,
J. Hossain,
K. Mannoor,
Y. A. Begum,
G. Mohi,
M. A. Salam,
R. B. Sack, and A.-M. Svennerholm.
1997.
Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1.
Infect. Immun.
65:3571-3576[Abstract].
|
| 20.
|
Stroeher, U. H.,
K. E. Jedani,
B. K. Dredge,
R. Morona,
M. H. Brown,
L. E. Karageorgos,
M. J. Albert, and P. A. Manning.
1995.
Genetic rearrangements in the rfb regions of Vibrio cholerae O1 and O139.
Proc. Natl. Acad. Sci. USA
92:10374-10378[Abstract/Free Full Text].
|
| 21.
|
Tacket, C. O.,
G. Losonsky,
J. P. Nataro,
L. Comstock,
J. Michalski,
R. Edelman,
J. B. Kaper, and M. M. Levine.
1995.
Initial clinical studies of CVD112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge.
J. Infect. Dis.
172:883-886[Medline].
|
| 22.
|
Voss, E., and S. R. Attridge.
1993.
In vitro production of toxin-coregulated pili by Vibrio cholerae El Tor.
Microb. Pathog.
15:255-268[CrossRef][Medline].
|
| 23.
|
Waldor, M. K.,
R. Colwell, and J. J. Mekalanos.
1994.
The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants.
Proc. Natl. Acad. Sci. USA
91:11388-11392[Abstract/Free Full Text].
|
Clinical and Diagnostic Laboratory Immunology, May 2000, p. 444-450, Vol. 7, No. 3
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Qadri, F., Svennerholm, A.-M., Shamsuzzaman, S., Bhuiyan, T. R., Harris, J. B., Ghosh, A. N., Nair, G. B., Weintraub, A., Faruque, S. M., Ryan, E. T., Sack, D. A., Calderwood, S. B.
(2005). Reduction in Capsular Content and Enhanced Bacterial Susceptibility to Serum Killing of Vibrio cholerae O139 Associated with the 2002 Cholera Epidemic in Bangladesh. Infect. Immun.
73: 6577-6583
[Abstract]
[Full Text]
-
Attridge, S. R., Wallerstrom, G., Qadri, F., Svennerholm, A.-M.
(2004). Detection of Antibodies to Toxin-Coregulated Pili in Sera from Cholera Patients. Infect. Immun.
72: 1824-1827
[Abstract]
[Full Text]
-
Attridge, S. R., Johansson, C., Trach, D. D., Qadri, F., Svennerholm, A.-M.
(2002). Sensitive Microplate Assay for Detection of Bactericidal Antibodies to Vibrio cholerae O139. CVI
9: 383-387
[Abstract]
[Full Text]